You are here

Bristol-Myers Squibb Signs Deal with UN Group for Generic Hepatitis C Drug

Drugmakers anywhere in the world can develop generic versions of Daklinza

A United Nations-backed organization says it has signed a deal with Bristol-Myers Squibb to allow generic versions of the company's hepatitis C drug to be sold in 112 low- and middle-income countries, Reuters reports.

The drug, daclatasvir (Daklinza, Bristol-Myers Squibb), is on the World Health Organization (WHO) list of essential medicines. Hepatitis C affects about 150 million people globally and kills around half a million each year, the World Health Organization estimates. The Medicines Patent Pool said that daclatasvir would now be available to nearly two-thirds of people affected by the disease in low- and middle-income countries.

The list price in the United States for daclatasvir is $63,000 for a 12-week regimen, or about $750 per day at wholesale costs, according to pharmacy benefits manager Express Scripts. Other drugs used to treat hepatitis C include Gilead Sciences' sofosbuvir (Sovaldi, Gilead Science). A single sofosbuvir pill costs $1,000 in the United States, according to Express Scripts.

The deal with Bristol-Myers allows drugmakers anywhere in the world to develop generic versions of daclatasvir.

The Medicines Patent Pool had earlier signed a deal with Bristol-Myers for generic versions of its HIV treatment atazanavir (Reyataz).

Source: Reuters, November 24, 2015.

Recent Headlines

Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients